Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Clover Meds LLC dba Clover Meds
WARNING LETTER
•Clover Meds LLC dba Clover Meds•March 1, 2026

Clover Meds LLC dba Clover Meds – FDA Warning Letter, Mar 1, 2026

Record Details

The U.S. Food and Drug Administration (FDA) issued a warning letter to Clover Meds LLC, doing business as Clover Meds, following a review of the company’s website in March 2026. The FDA identified significant violations regarding the marketing and labeling of compounded semaglutide and tirzepatide drug products. The primary issues involve false and misleading representations that violate the Federal Food, Drug, and Cosmetic Act. Specifically, the company’s website displays product labels suggesting Clover Meds is the manufacturer when it is not. Furthermore, the company claims its products are sourced from “FDA-licensed facilities.” The FDA clarified that this terminology is deceptive because the agency does not license or approve compounding pharmacies or their specific compounded products. These misrepresentations cause the drugs to be classified as misbranded under sections 502 and 301 of the Act. To achieve compliance, Clover Meds is required to investigate the root causes of these violations and implement corrective actions. The company must provide a written response within 15 business days outlining its plan to resolve the issues. Required actions include identifying the actual producers of the drugs, providing representative labeling samples, and removing all misleading claims from their website. Failure to address these violations may result in legal action, such as product seizures or injunctions.

Company
Clover Meds LLC dba Clover Meds
Inspection date
March 1, 2026
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Matthew J. Lash (Acting Director)
View Company Profile

ID · 9970cd0d-7b51-4020-bd91-d31e1f0d2e74

Violation Codes10
FD&C Act 502(a)FD&C Act 502(bb)21 U.S.C. 352(a)21 U.S.C. 352(bb)FD&C Act 301(a)21 U.S.C. 33121 U.S.C. 331(c)FD&C Act 301(c)FD&C Act 503AFD&C Act 503B

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Clover Meds LLC dba Clover Meds
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.